Science Explorer Back to mapMap
Discussion
Institution · Immatics Biotechnologies (Germany)

Most cited papers from Immatics Biotechnologies (Germany)

Immatics Biotechnologies (Germany)

What are the most cited papers from Immatics Biotechnologies (Germany)?

The most cited paper from Immatics Biotechnologies (Germany) is "Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing" (Mahesh Chandra Yadav, Suchit Jhunjhunwala, Qui T. Phung et al., 2014), with 1,217 citations. Next come "Actively personalized vaccination trial for newly diagnosed glioblastoma" (954) and "Cancer classification using the Immunoscore: a worldwide task force" (807).

Showing 50 of 59 papers. Every paper with more than 33 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing Mahesh Chandra Yadav, Suchit Jhunjhunwala, Qui T. Phung et al. · Nature 25 Nov 2014 1,217
2 Actively personalized vaccination trial for newly diagnosed glioblastoma Norbert Hilf et al. · Nature 19 Dec 2018 954
3 Cancer classification using the Immunoscore: a worldwide task force Jérôme Galon et al. · Journal of Translational Medicine Open access 3 Oct 2012 807
4 Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival Steffen Walter et al. · Nature Medicine 29 Jul 2012 793
5 SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition Annika Nelde et al. · Nature Immunology Open access 30 Sep 2020 647
6 Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses M. Hipp, Norbert Hilf, Steffen Walter et al. · Blood Mar 2008 290
7 Improved Ribo-seq enables identification of cryptic translation events Florian Erhard, Anne Halenius, Cosima Zimmermann et al. · Nature Methods Open access 12 Mar 2018 236
8 Immune Tolerance to Tumor Antigens Occurs in a Specialized Environment of the Spleen Stefano Ugel, Elisa Peranzoni, Giacomo Desantis et al. · Cell Reports Open access Sep 2012 224
9 IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial Brian I. Rini et al. · The Lancet Oncology 7 Oct 2016 221
10 Metabonomic fingerprints of fasting plasma and spot urine reveal human pre-diabetic metabolic traits Xinjie Zhao, Jens Fritsche, Jiangshan Wang et al. · Metabolomics Open access 5 Mar 2010 208
11 Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy Valérie Dutoit, Christel C. Herold‐Mende, Norbert Hilf et al. · Brain Open access 14 Feb 2012 205
12 The immunopeptidomic landscape of ovarian carcinomas Heiko J. Schuster et al. · Proceedings of the National Academy of Sciences Open access Nov 2017 204
13 Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study Susanna Mandruzzato, Sven Brandau, Cedrik Michael Britten et al. · Cancer Immunology Immunotherapy Open access 4 Jan 2016 200
14 Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma Markus Löffler et al. · Genome Medicine Open access 30 Apr 2019 181
15 Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas Katrin Aslan et al. · Nature Communications Open access 18 Feb 2020 173
16 A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma R. Rampling, Sharon Peoples, Paul James Mulholland et al. · Clinical Cancer Research Open access 25 May 2016 169
17 RNA editing derived epitopes function as cancer antigens to elicit immune responses Minying Zhang et al. · Nature Communications Open access 19 Sep 2018 158
18 Defining the critical hurdles in cancer immunotherapy Bernard A. Fox et al. · Journal of Translational Medicine Open access105 authors Dec 2011 154
19 Medium Chain Acylcarnitines Dominate the Metabolite Pattern in Humans under Moderate Intensity Exercise and Support Lipid Oxidation Rainer Lehmann, Xinjie Zhao, Cora Weigert et al. · PLoS ONE Open access 12 Jul 2010 150
20 The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays Cedrik Michael Britten et al. · Cancer Immunology Immunotherapy Open access 24 Aug 2007 142
21 Interaction of TLR2 and TLR4 Ligands with the N-terminal Domain of Gp96 Amplifies Innate and Adaptive Immune Responses Tobias Warger, Nobert Hilf, Gerd Rechtsteiner et al. · Journal of Biological Chemistry Open access 6 Jun 2006 136
22 T Cell Assays and MIATA: The Essential Minimum for Maximum Impact Cedrik Michael Britten et al. · Immunity Open access Jul 2012 131
23 The T�bingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy Harpreet Singh‐Jasuja, Niels Emmerich, Hans‐Georg Rammensee · Cancer Immunology Immunotherapy Open access Mar 2004 125
24 NONEXPRESSOR OF PATHOGENESIS‐RELATED PROTEINS1 (NPR1) and some NPR1‐related proteins are sensitive to salicylic acid Felix Maier, SYLVIA ZWICKER, Angela G. Hückelhoven et al. · Molecular Plant Pathology Open access 4 Aug 2010 125
25 Unveiling the Peptide Motifs of HLA-C and HLA-G from Naturally Presented Peptides and Generation of Binding Prediction Matrices Moreno Di Marco, Heiko J. Schuster, Linus Backert et al. · The Journal of Immunology 13 Sep 2017 121
26 Human peripheral γδ T cells possess regulatory potential Anja Andrea Kühl, Nina N. Pawlowski, Katja Grollich et al. · Immunology Open access 11 Sep 2009 108
27 Dietary tryptophan links encephalogenicity of autoreactive T cells with gut microbial ecology Jana K. Sonner et al. · Nature Communications Open access 25 Oct 2019 105
28 Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance Norma Bloy et al. · Immunological Reviews Review 13 Oct 2017 105
29 Differential expression of genes encoding tight junction proteins in colorectal cancer: frequent dysregulation of claudin-1, -8 and -12 Jörn Gröne, B. Weber, Eike Staub et al. · International Journal of Colorectal Disease 17 Oct 2006 96
30 Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient Markus Löffler et al. · Journal of Hepatology Open access 9 Jul 2016 92
31 HLA ligandome tumor antigen discovery for personalized vaccine approach Hans‐Georg Rammensee, Harpreet Singh‐Jasuja · Expert Review of Vaccines Open access Oct 2013 90
32 Novel methylated triterpenoids of the gammacerane series from the nitrogen‐fixing bacterium Bradyrhizobium japonicum USDA 110 Jean‐Michel Bravo, Michael Perzl, Thomas Härtner et al. · European Journal of Biochemistry Open access Mar 2001 88
33 The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy Tatjana Bilich et al. · Blood Open access 11 Dec 2018 78
34 Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma Jürgen Christian Becker, Mads Hald Andersen, Valeska Hofmeister-Müller et al. · Cancer Immunology Immunotherapy Open access 7 May 2012 77
35 Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma Markus W. Löffler et al. · Clinical Cancer Research Open access 14 Apr 2022 74
36 A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer Hans-Georg Rammensee et al. · Journal for ImmunoTherapy of Cancer Open access 15 Nov 2019 72
37 Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma Bracha Shraibman et al. · Molecular & Cellular Proteomics Open access Jun 2019 71
38 Unexpected Abundance of HLA Class II Presented Peptides in Primary Renal Cell Carcinomas Jörn Dengjel, Maria-Dorothea Nastke, Cécile Gouttefangeas et al. · Clinical Cancer Research 15 Jul 2006 67
39 Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial Martin Wermke et al. · Nature Medicine Open access 9 Apr 2025 64
40 Thinking Outside the Gate: Single-Cell Assessments in Multiple Dimensions Pia Kvistborg, Cécile Gouttefangeas, Nima Aghaeepour et al. · Immunity Open access Apr 2015 62
41 Erosion of human X chromosome inactivation causes major remodeling of the iPSC proteome Alejandro J. Brenes, Harunori Yoshikawa, Dalila Bensaddek et al. · Cell Reports Open access Apr 2021 61
42 The regulatory landscape for actively personalized cancer immunotherapies Cedrik Michael Britten, Harpreet Singh‐Jasuja, Bruno Flamion et al. · Nature Biotechnology Oct 2013 61
43 Improving the efficacy of cancer immunotherapy John P. Copier, Angus George Dalgleish, Cedrik Michael Britten et al. · European Journal of Cancer 22 Jan 2009 53
44 Understanding the constitutive presentation of MHC class I immunopeptidomes in primary tissues Peter Kubiniok, Ana Marcu, Leon Bichmann et al. · iScience Open access 17 Jan 2022 51
45 IMA901: A multi-peptide cancer vaccine for treatment of renal cell cancer Alexandra Kirner, Andrea Mayer-Mokler, Carsten Reinhardt · Human Vaccines & Immunotherapeutics Open access 2 Nov 2014 51
46 MHC-I Ligand Discovery Using Targeted Database Searches of Mass Spectrometry Data: Implications for T-Cell Immunotherapies John Patrick Murphy, Prathyusha Konda, Daniel Johannes Kowalewski et al. · Journal of Proteome Research Open access 28 Feb 2017 49
47 High-throughput peptide-MHC complex generation and kinetic screenings of TCRs with peptide-receptive HLA-A*02:01 molecules Andreas Moritz, Raghavendra Anjanappa, Claudia Simone Wagner et al. · Science Immunology 5 Jul 2019 47
48 Translating Immunopeptidomics to Immunotherapy‐Decision‐Making for Patient and Personalized Target Selection Jens Fritsche, Barbara Rakitsch, Franziska Hoffgaard et al. · PROTEOMICS Open access 5 Mar 2018 45
49 Quantitative immunopeptidomics reveals a tumor stroma–specific target for T cell therapy Gloria B. Kim et al. · Science Translational Medicine Open access 31 Aug 2022 44
50 HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy Annika Nelde, Daniel Johannes Kowalewski, Linus Backert et al. · OncoImmunology Open access 13 Apr 2017 43

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.